Literature DB >> 1378875

Serum AFP, hCG and CEA in the management of patients with testicular, ovarian and extragonadal germ cell tumors.

M S Motawy1, J J Szymendera, H al-Jazzaf, A E Behbehani, M O Foudeh, A K Ebraheem, M Y Nasralla, M A Ali.   

Abstract

Serum levels of AFP, hCG and CEA were initially and serially measured in 59 patients with testicular germ cell tumors, and serially in 37 with ovarian and 3 with extragonadal germ cell tumors. Patients with seminoma/dysgerminoma or mature teratoma had normal serum AFP and sporadically slightly elevated hCG. Some patients with embryonal carcinoma, pure or with admixture of seminoma, had serum AFP elevated to maximum 100 U/ml, yet its use for monitoring therapy was limited. Patients with yolk sac tumors had elevated AFP and sometimes CEA levels, those with choriocarcinoma had elevated hCG, and those with compound tumors had one or more of the markers highly elevated. High AFP and/or hCG levels indicated the presence of the relevant tumor cells both in the primary and in residual tumor and/or metastases, also those missed in histological material, and thus were useful in restaging. Unfortunately, their absence in serum did not exclude the presence of marker-negative subpopulations of tumor cells. Changes in marker values paralleled the effects of treatment: the level increasing from any nadir heralded recurrence in patients in remission; elevated or increasing levels during therapy implied resistance to the therapy; decreasing levels indicated regression even though a return to the normal range did not mean eradication of all tumor cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378875     DOI: 10.1177/172460089200700202

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  1 in total

1.  Association between Helicobacter pylori infection and tumor markers: an observational retrospective study.

Authors:  Mei-Yan Xu; Bing Cao; Yan Chen; Natalie Musial; Shuai Wang; Jian Yin; Lan Liu; Qing-Bin Lu
Journal:  BMJ Open       Date:  2018-08-23       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.